Trial Profile

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary) ; Acalabrutinib; Venetoclax
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Acronyms CELESTIAL-TNCLL-2
Sponsors BeOne Medicines

21 May 2026 According to BeOne Medicines media release, data from this trial will be presented at 2026 European Hematology Association (EHA) Congress.
21 May 2026 According to BeOne Medicines media release, trial design will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2, Chicago).
26 Feb 2026 According to BeOne Medicines media release, first patient has been enrolled in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com